Intravitreal steroids and anti-VEGF therapy beneficial in treatment of resistant Wet-AMD

USA: For the treatment of Wet-Age Related Macular Degeneration (Wet-AMD), a combination of steroids and anti-VEGF offers obvious anatomic improvement in resistant choroidal neovascularization (CNV), says a study presented at Association for Research in Vision and Ophthalmology (ARVO) 2022 Meeting.

The therapeutic utility of concurrent intravitreal steroids with anti-VEGF (inhibitory vascular endothelial growth factor) in choroidal neovascularization refractory to standard therapy is debatable. Alexandra Warter and colleagues assessed anatomic and visual changes following a simultaneous intervention in long-cohort research aiming to investigate the therapeutic safety and effectiveness of adjuvant steroids with anti-VEGF in resistant chronic Wet-Age Related Macular Degeneration.

Researchers conducted a retrospective observational clinical analysis on a sequential cohort of patients' eyes with persistent choroidal neovascularization that was architecturally resistant to aggressive high-dose high-frequency (HDHF) monotherapy for this investigation (i.e.: monthly 4 mg aflibercept). A total of 12 eyes were investigated with unresponsive choroidal neovascularization despite therapy with alternating anti-VEGF medications. Following high-dose high-frequency therapy, resistance was defined as persisting retinal fluid. The combination consisted of administering anti-VEGF and steroids at the same time, followed by two weeks of preventive topical antiglaucoma medicine. For four months, slit-lamp, visual acuity (BCVA), intraocular pressure (IOP), and optical coherence tomography (OCT) measures of the central retinal thickness (CRT) were taken every four weeks. Baseline predictors of therapy effectiveness were examined. Changes in BCVA, IOP, and CRT were among the outcomes.